Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

Shigesato Inoue; Hiroaki Ogata; Yoichi Dotake; Koichi Takagi; Ayaka Shiota; Yumiko Ishii; Kentaro Tanaka; Keiko Kan-O; Hiromasa Inoue

doi:10.1016/j.jacig.2025.100448

Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

J Allergy Clin Immunol Glob. 2025 Mar 8;4(2):100448. doi: 10.1016/j.jacig.2025.100448. eCollection 2025 May.

Authors

Shigesato Inoue^{1

2}, Hiroaki Ogata^{1

3}, Yoichi Dotake⁴, Koichi Takagi⁴, Ayaka Shiota³, Yumiko Ishii¹, Kentaro Tanaka⁴, Keiko Kan-O^{1

5}, Hiromasa Inoue⁴

Affiliations

¹ Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
² Department of Respiratory Medicine, National Hospital Organization Fukuokahigashi Medical Center, Koga, Fukuoka, Japan.
³ Department of Respiratory Medicine, NHO Fukuoka National Hospital, Minami-ku, Fukuoka.
⁴ Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
⁵ Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Abstract

Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving tezepelumab treatment are presented.

Keywords: Asthma control; nasal polyps; rhinosinusitis; severe asthma; tezepelumab.

Publication types

Case Reports